Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: an overview of systematic reviews with meta-analyses
This overview summarizes evidence for the efficacy and safety of bortezomib, thalidomide,
and lenalidomide in patients with multiple myeloma. We searched the Medline, Scopus, and …
and lenalidomide in patients with multiple myeloma. We searched the Medline, Scopus, and …
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
PG Richardson, W Xie, S Jagannath… - Blood, The Journal …, 2014 - ashpublications.org
In this prospective, multicenter, phase 2 study, 64 patients with relapsed or relapsed and
refractory multiple myeloma (MM) received up to 8 21-day cycles of bortezomib 1.0 mg/m2 …
refractory multiple myeloma (MM) received up to 8 21-day cycles of bortezomib 1.0 mg/m2 …
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study
M Roussel, V Lauwers-Cances, M Macro… - Blood, The Journal …, 2022 - ashpublications.org
High-dose melphalan (HDM) and transplantation are recommended for eligible patients with
multiple myeloma. No other conditioning regimen has proven to be more effective and/or …
multiple myeloma. No other conditioning regimen has proven to be more effective and/or …
Bortezomib for the treatment of previously untreated multiple myeloma
A Romano, C Conticello, F Di Raimondo - Immunotherapy, 2013 - Taylor & Francis
Management of multiple myeloma (MM) has been drastically changed in the last 10 years
thanks to the introduction of novel agents, which, combined with the backbone of classical …
thanks to the introduction of novel agents, which, combined with the backbone of classical …
Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma
RM Koerber, SAE Held, A Heine, P Kotthoff… - … hematology & oncology, 2015 - Springer
Background Multiple myeloma (MM) is a clonal B cell malignancy characterized by
proliferation of malignant plasma cells in the bone marrow. Despite high-dose melphalan …
proliferation of malignant plasma cells in the bone marrow. Despite high-dose melphalan …
[HTML][HTML] Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model
Multiple myeloma is a malignant still incurable plasma cell disorder. This is due to refractory
disease relapse, immune impairment, and development of multi-drug resistance. The growth …
disease relapse, immune impairment, and development of multi-drug resistance. The growth …
[HTML][HTML] Thrombin generation in newly diagnosed multiple myeloma during the first three cycles of treatment: An observational cohort study
E Chalayer, B Tardy‐Poncet, L Karlin… - Research and practice …, 2019 - Elsevier
Background Multiple myeloma (MM) is associated with a high risk of thrombosis, particularly
during the first months of treatment including immunomodulatory drugs (IMiDs). There is no …
during the first months of treatment including immunomodulatory drugs (IMiDs). There is no …
Bortezomib and lenalidomide as front-line therapy for multiple myeloma
Y Zou, M Lin, Z Sheng, S Niu - Leukemia & lymphoma, 2014 - Taylor & Francis
The objective of the study was to investigate the effects and safety of novel agents such as
bortezomib and lenalidomide in the treatment of newly diagnosed patients with multiple …
bortezomib and lenalidomide in the treatment of newly diagnosed patients with multiple …
Identification of four key biomarkers and small molecule drugs in nasopharyngeal carcinoma by weighted gene co-expression network analysis
X Pan, JH Liu - Bioengineered, 2021 - Taylor & Francis
Nasopharyngeal carcinoma (NPC) is a heterogeneous carcinoma whose underlying
molecular mechanisms involved in tumor initiation, progression, and migration are largely …
molecular mechanisms involved in tumor initiation, progression, and migration are largely …
The tale of lenalidomide clinical superiority over thalidomide and regulatory and cost-effectiveness issues
FJR Paumgartten - Ciência & Saúde Coletiva, 2019 - SciELO Brasil
Abstract In April 2017, the National Sanitary Surveillance Agency (ANVISA-Brazil) approved
lenalidomide (LEN) for multiple myeloma (MM) and myelodysplastic syndrome. ANVISA had …
lenalidomide (LEN) for multiple myeloma (MM) and myelodysplastic syndrome. ANVISA had …